Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial

European Journal of Cancer

Volumn 35, Issue 6, 1999, Pages 946-952

  Van Driel, Wj ^a   Ressing, M E ^a   Renter, G G ^a   Brandt, R M P ^a   Krul, E J T ^a   Van Rossum, A B ^b   Schuuring, E ^a   Offringa, R ^a   Bauknecht, T ^c   Tamm Hermelink, A ^c   Van Dam, P A ^d   Fleuren, Gj ^a   Kast, W M ^e   Melief, CjM ^a   Trimbos, J B ^a  

^a Department of Gynaecology ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cervix; CTL; HPV; Immunotherapy; Neoplasm; Peptide; Vaccination

Indexed keywords

HLA A ANTIGEN; IMMUNOLOGICAL ADJUVANT; VIRUS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHEMA; FEMALE; HUMAN; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TERMINAL DISEASE; UTERINE CERVIX CARCINOMA; VACCINATION; WART VIRUS;

ADULT; AGED; CANCER VACCINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0033153564     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00048-9     Document Type: Article

References (30)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993, 54, 594-606.
2. Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF. Stage IB and IIA cervical cancer with negative lymph nodes: The role of adjuvant radiotherapy after radical hysterectomy. Gynec Oncol 1997, 66, 31-35.
3. Delgado G, Bundy B, Zaino R, Sevin B, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynec Oncol 1990, 38, 352-357.
4. Bonomi P, Blessing J, Ball H, Hanjani P, Disaia PJ. A phase II evaluation of Cis-platin and 5-fluoro-uracil in patients with advanced squamous cell carcinoma of the cervix: A Gynaecologic Oncology Group Study. Gynec Oncol 1989, 34, 357-361.
5. Alberts DS, Kronmal R, Baker LH, et al. Phase II randomized trial of Cis-platin chemotherapy regimen in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group Study. J Clin Oncol 1987, 5, 1791-1795.
6. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995, 87, 796-802.
7. McMichael AJ, Bodmer WF. Cancer Surveys: A New Look at Tumour Immunology. New York, Cold Spring Harbor Laboratory Press, 1992.
8. Tweddel G, Heller P, Cunnane M, Multhaupt H, Roth K. The correlation between HIV seropositivity, cervical dysplasia, and HPV subtypes 6/11, 16/18, 31/33/35. Gynec Oncol 1994, 52, 161-164.
9. Hilders CGJM, Houbiers JGA, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ. Association between hla-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993, 69, 651-659.
10. Käst WM, Brandt RMP, Drijfhout JW, Melief CJM. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993, 14, 115-120.
11. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994, 152, 3904-3912.
12. Ressing ME, Sette A, Brandt RMP, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995, 154, 5934-5943.
13. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996, 56, 582-588.
14. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997, 57, 2943-2950.
15. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23, 2242-2249.
16. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, et al. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunology 1995, 25, 2638-2641.
17. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1, 751-761.
18. World Health Organization: WHO Handbook for Reporting Result of Cancer Treatment. Geneva, Switzerland, 1979, Publication no. 48, 1979.
19. Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. Lab Invest 1992, 67, 166-174.
20. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-cancer Drugs 1997, 8, 657-661.
21. Ishiguro T, Sugitachi I, Katoh K. T and B lymphocytes in patients with squamous cell carcinoma of the uterine cervix. Gynec Oncol 1980, 9, 80-85.
22. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988, 41, 562-567.
23. Campbell AC, Hersey P, MacLennan IC, Kay HE, Pike MC. Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J 1973, 2, 385-388.
24. Hoppe RT. Effects of irradiation on the human immune system. Front Rad Ther Oncol 1989, 23, 140-149.
25. Celluzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996, 183, 283-287.
26. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine 1995, 1, 1297-1302.
27. De Bruijn MLH, Schuurhuis DH, Vierboom MPM, et al. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV 16-induced tumor cells. Cancer Res 1998, 58, 724-731.
28. Boursnell MEG, Rutherford E, Hickling JK, et al. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996, 14, 1485-1494.
29. Roden RBS, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996, 70, 3298-3301.
30. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model. Proc Natl Acad Sci USA 1998, 95, 1800-1805.